HLA genetic polymorphisms and prognosis of patients with COVID-19

Abstract

\n Objective\n Different genetic polymorphisms of human leukocyte antigen (HLA) have been associated with the risk and prognosis of autoimmune and infectious diseases. The objectives of this study were to determine whether there is an association between HLA genetic polymorphisms and the susceptibility to and mortality of coronavirus disease 2019 (COVID-19) patients.\n \n Design\n Observational and prospective study.\n \n Setting\n Eight Intensive Care Units (ICU) from 6 hospitals of Canary Islands (Spain).\n \n Patients\n COVID-19 patients admitted in ICU and healthy subjects.\n \n Interventions\n Determination of HLA genetic polymorphisms.\n \n Main variable of interest\n Mortality at 30 days.\n \n Results\n A total of 3886 healthy controls and 72 COVID-19 patients (10 non-survivors and 62 survivor patients at 30 days) were included. We found a trend to a higher rate of the alleles HLA-A*32 (p\n =0.004) in healthy controls than in COVID-19 patients, and of the alleles HLA-B*39 (p\n =0.02) and HLA-C*16 (p\n =0.02) in COVID-19 patients than in healthy controls; however, all these p-values were not significant after correction for multiple comparisons. Logistic regression analysis showed that the presence of certain alleles was associated with higher mortality, such as the allele HLA-A*11 after controlling for SOFA (OR=7.693; 95% CI=1.063–55.650; p\n =0.04) or APACHE-II (OR=11.858; 95% CI=1.524–92.273; p\n =0.02), the allele HLA-C*01 after controlling for SOFA (OR=11.182; 95% CI=1.053–118.700; p\n =0.04) or APACHE-II (OR=17.604; 95% CI=1.629–190.211; p\n =0.02), and the allele HLA-DQB1*04 after controlling for SOFA (OR=9.963; 95% CI=1.235–80.358; p\n =0.03).\n \n Conclusions\n The new finding from our preliminary study of small sample size was that HLA genetic polymorphisms could be associated with COVID-19 mortality; however, studies with a larger sample size before definitive conclusions can be drawn.\n